A biotechnology company developing medicines that treat intractable diseases by silencing the genes that cause them.
4 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Arrowhead Pharmaceuticals, Inc..
The 1 sources with the most insights about Arrowhead Pharmaceuticals, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Strongly positive clinical and fundamental view following positive clinical trial data and event reduction updates.
Mentioned as a partner to Sarepta that accepted stock instead of cash, a move seen as a bullish sign of financial strength for Sarepta.
Mentioned positively as a partner with Sarepta for a new siRNA platform, which helps diversify Sarepta's pipeline into new disease areas.
Strongly positive clinical and fundamental view following positive clinical trial data and event reduction updates.
Mentioned as a partner to Sarepta that accepted stock instead of cash, a move seen as a bullish sign of financial strength for Sarepta.
Mentioned positively as a partner with Sarepta for a new siRNA platform, which helps diversify Sarepta's pipeline into new disease areas.
Other assets that creators frequently mention in the same content as Arrowhead Pharmaceuticals, Inc..
The most active sources covering Arrowhead Pharmaceuticals, Inc. (ARWR) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 4 AI-extracted insights about Arrowhead Pharmaceuticals, Inc. (ARWR) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Arrowhead Pharmaceuticals, Inc. (ARWR) most frequently also discuss SRPT, ABVX, AMD, IONQ, MU. See the "Discussed alongside" section above for full asset pages.